Redox Properties and Activity
of Iron–Citrate
Complexes: Evidence for Redox Cycling
- Publication date
- 2015
- Publisher
Abstract
Iron in iron overload disease is
present as non-transferrin-bound
iron, consisting of iron, citrate, and albumin. We investigated the
redox properties of iron citrate by electrochemistry, by the kinetics
of its reaction with ascorbate, by ESR, and by analyzing the products
of reactions of ascorbate with iron citrate complexes in the presence
of H<sub>2</sub>O<sub>2</sub> with 4-hydroxybenzoic acid as a reporter
molecule for hydroxylation. We report −0.03 V < <i>E</i>°′ > +0.01 V for the (Fe<sup>3+</sup>–cit/Fe<sup>2+</sup>–cit) couple. The first step in the reaction of iron
citrate with ascorbate is the rapid formation of mixed complexes of
iron with citrate and ascorbate, followed by slow reduction to Fe<sup>2+</sup>–citrate with <i>k</i> = ca. 3 M<sup>–1</sup> s<sup>–1</sup>. The ascorbyl radical is formed by iron citrate
oxidation of Hasc<sup>–</sup> with <i>k</i> = ca.
0.02 M<sup>–1</sup> s<sup>–1</sup>; the majority of
the ascorbyl radical formed is sequestered by complexation with iron
and remains EPR silent. The hydroxylation of 4-hydroxybenzoic acid
driven by the Fenton reduction of iron citrate by ascorbate in the
presence of H<sub>2</sub>O<sub>2</sub> proceeds in three phases: the
first phase, which is independent of the presence of O<sub>2</sub>, is revealed as a nonzero intercept that reflects the rapid reaction
of accumulated Fe<sup>2+</sup> with H<sub>2</sub>O<sub>2</sub>; the
intermediate oxygen-dependent phase fits a first-order accumulation
of product with <i>k</i> = 5 M<sup>–1</sup> s<sup>–1</sup> under aerobic and <i>k</i> = 13 M<sup>–1</sup> s<sup>–1</sup> under anaerobic conditions; the slope of the
final linear phase is ca. <i>k</i> = 5 × 10<sup>–2</sup> M<sup>–1</sup> s<sup>–1</sup> under both aerobic and
anaerobic conditions. Product yields under aerobic conditions are
greater than predicted from the initial concentration of iron, but
they are less than predicted for continuous redox cycling in the presence
of excess ascorbate. The ongoing formation of hydroxylated product
supports slow redox cycling by iron citrate. Thus, when H<sub>2</sub>O<sub>2</sub> is available, iron–citrate complexes may contribute
to pathophysiological manifestations of iron overload diseases